guest ::
| Home > Publications database > Hypoxic HPV-Positive Cancer Cells Are Particularly Sensitive to the Pro-Senescent Effects of B-MYB Repression Due to the Lack of Compensatory A-MYB Induction. > print |
| Home > Publications database > Hypoxic HPV-Positive Cancer Cells Are Particularly Sensitive to the Pro-Senescent Effects of B-MYB Repression Due to the Lack of Compensatory A-MYB Induction. > print |
| 001 | 301746 | ||
| 005 | 20250608020936.0 | ||
| 024 | 7 | _ | |a 10.1002/jmv.70422 |2 doi |
| 024 | 7 | _ | |a pmid:40444458 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC12123558 |2 pmc |
| 024 | 7 | _ | |a 0146-6615 |2 ISSN |
| 024 | 7 | _ | |a 1096-9071 |2 ISSN |
| 024 | 7 | _ | |a altmetric:177685784 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2025-01130 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Velimirovic, Milica |0 P:(DE-He78)0a4c58c6737b30b65df3ed36acc08d4f |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Hypoxic HPV-Positive Cancer Cells Are Particularly Sensitive to the Pro-Senescent Effects of B-MYB Repression Due to the Lack of Compensatory A-MYB Induction. |
| 260 | _ | _ | |a Bognor Regis [u.a.] |c 2025 |b Wiley |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1748871428_11125 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:D365#LA:D365# |
| 520 | _ | _ | |a Tumor hypoxia is typically linked to increased therapy resistance and poor prognosis of many malignancies, including HPV-positive cancers. One possible resistance mechanism is the increased resistance of hypoxic tumor cells to cellular senescence. It is thus highly interesting to identify strategies which could increase their pro-senescent susceptibility. In comparative analyses of normoxic and hypoxic HPV-positive cancer cells, we here uncover that the interconnection between B-MYB and its paralog A-MYB plays a key role for their senescence response, but shows a differential regulation under normoxia and hypoxia. In specific, we demonstrate that the pro-senescent response to B-MYB loss is counteracted by a compensatory upregulation of A-MYB under normoxia. Therefore, efficient induction of senescence in normoxic cells requires the downregulation of both B-MYB and A-MYB. Interestingly, this compensatory A-MYB induction is absent under hypoxia, rendering hypoxic cancer cells particularly sensitive to the pro-senescent effect of B-MYB repression. We further show that these regulatory effects are not confined to HPV-positive cancer cells, indicating that they could be broadly conserved between different cancer types. Collectively, our findings reveal that hypoxic cancer cells are particularly sensitive to B-MYB inhibition, which could provide a new strategy to target this therapeutically challenging cancer cell population. |
| 536 | _ | _ | |a 314 - Immunologie und Krebs (POF4-314) |0 G:(DE-HGF)POF4-314 |c POF4-314 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a A‐MYB |2 Other |
| 650 | _ | 7 | |a B‐MYB |2 Other |
| 650 | _ | 7 | |a cervical cancer |2 Other |
| 650 | _ | 7 | |a human papillomavirus (HPV) |2 Other |
| 650 | _ | 7 | |a hypoxia |2 Other |
| 650 | _ | 7 | |a senescence |2 Other |
| 650 | _ | 7 | |a Trans-Activators |2 NLM Chemicals |
| 650 | _ | 7 | |a MYBL2 protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a MYB protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a Cell Cycle Proteins |2 NLM Chemicals |
| 650 | _ | 7 | |a Proto-Oncogene Proteins c-myb |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Cellular Senescence |2 MeSH |
| 650 | _ | 2 | |a Cell Line, Tumor |2 MeSH |
| 650 | _ | 2 | |a Trans-Activators: genetics |2 MeSH |
| 650 | _ | 2 | |a Trans-Activators: metabolism |2 MeSH |
| 650 | _ | 2 | |a Cell Hypoxia |2 MeSH |
| 650 | _ | 2 | |a Papillomaviridae |2 MeSH |
| 650 | _ | 2 | |a Papillomavirus Infections |2 MeSH |
| 650 | _ | 2 | |a Cell Cycle Proteins |2 MeSH |
| 650 | _ | 2 | |a Proto-Oncogene Proteins c-myb |2 MeSH |
| 700 | 1 | _ | |a Avenhaus, Alicia |0 P:(DE-He78)b99b271e0ad2dea9ba3ebefc35af9a76 |b 1 |u dkfz |
| 700 | 1 | _ | |a Lohrey, Claudia |0 P:(DE-He78)2ebb2998d182d99478108ef2cb4b804c |b 2 |u dkfz |
| 700 | 1 | _ | |a Bulkescher, Julia |0 P:(DE-He78)c04ec6ab9480d74da506d656185ec7d2 |b 3 |u dkfz |
| 700 | 1 | _ | |a Hoppe-Seyler, Felix |0 P:(DE-He78)25779f8829ab7a7650e85a4cc871e6ac |b 4 |u dkfz |
| 700 | 1 | _ | |a Hoppe-Seyler, Karin |0 P:(DE-He78)97468f1980416a4376b44e701d25f24b |b 5 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1002/jmv.70422 |g Vol. 97, no. 6, p. e70422 |0 PERI:(DE-600)1475090-9 |n 6 |p e70422 |t Journal of medical virology |v 97 |y 2025 |x 0146-6615 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:301746 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)0a4c58c6737b30b65df3ed36acc08d4f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)b99b271e0ad2dea9ba3ebefc35af9a76 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)2ebb2998d182d99478108ef2cb4b804c |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)c04ec6ab9480d74da506d656185ec7d2 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)25779f8829ab7a7650e85a4cc871e6ac |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)97468f1980416a4376b44e701d25f24b |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-314 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Immunologie und Krebs |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2025-01-02 |w ger |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2025-01-02 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J MED VIROL : 2022 |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2025-01-02 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2025-01-02 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b J MED VIROL : 2022 |d 2025-01-02 |
| 920 | 2 | _ | |0 I:(DE-He78)D365-20160331 |k D365 |l Molek. Therapie virusassozierter Tumore |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)D365-20160331 |k D365 |l Molek. Therapie virusassozierter Tumore |x 0 |
| 920 | 0 | _ | |0 I:(DE-He78)D365-20160331 |k D365 |l Molek. Therapie virusassozierter Tumore |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)D365-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|